| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Address correspondence to: Dr. G.D. Puri, Department of Anaesthesia and Intensive Care, PGIMER, Chandigarh-160012, India. Phone: 91-172-549717; Fax: 91-172-744401; E-mail: gdpuri007{at}hotmail.com
| Abstract |
|---|
|
|
|---|
Methods: Piroxicam gel and EMLA cream were randomly applied on the dorsum of the right and left hand of ten volunteers who acted as their own control. A venous cannula was inserted (no iv infusion) and removed after one hour. Pain scores and signs of inflammation were noted at the cannulation site up to 48 hr.
Results: Pain scores with piroxicam gel were higher on cannulation and on advancement of the cannula (P < 0.05). Thereafter, pain scores were significantly higher with EMLA (P < 0.05). Blanching was present at all the peripheral venous sites treated with EMLA cream. Signs of inflammation (erythema, edema) were not more frequent with EMLA than with piroxicam (P > 0.05). Induration was more frequent with EMLA at six hours.
Conclusion: In volunteers EMLA cream is associated with less pain on cannulation and cannula advancement compared to piroxicam gel. Topical application of piroxicam gel before peripheral venous cannulation alleviates pain and, possibly, inflammation in the period subsequent to cannulation itself.
| Introduction |
|---|
|
|
|---|
Local anesthetics in one form or the other are commonly employed to overcome pain on cannulation.3 Apart from the benefit of rapidity of onset and effective pain relief, the use of local anesthetic agents is associated with a number of disadvantages, such as pin-prick pain on lidocaine sc infiltration4 and blanching of the skin and vasoconstriction following the topical application of eutectic mixture of local anesthetic (EMLA) cream.5 These agents do not seem to have any effect on subsequent inflammation. Topical NSAIDs, by virtue of their capacity to inhibit prostaglandin synthesis are expected to provide analgesia and decrease the inflammatory response to cannulation. Smith et al. found that topical ibuprofen did not alleviate pain secondary to venous cannulation, but they did not study its effect on inflammation.4 Topical piroxicam, a long-acting NSAID6 has been used as an adjuvant for postoperative analgesia in patients undergoing inguinal hernia repair.7
We evaluated the efficacy of topical piroxicam to prevent pain during and after venous cannulation and subsequent inflammation in adult volunteers.
| Methods |
|---|
|
|
|---|
A vein was marked on the dorsum of both hands. Piroxicam gel (Cipla, Ahmedabad, India) was applied on one hand and EMLA cream on the other hand (Astra Pharmaceuticals, NSW, Australia) of each subject based upon a computer generated random number. It was then covered with an occlusive dressing (Tegaderm, 3M Health Care, St. Paul, MN, USA) and a gauze bandage. The area of skin covered with gel (3.8 cm x 1.9 cm) and the amount of topical drug preparation (2 g) were standardized. Volunteers were blinded to the gel applied. The gel was wiped off with an alcohol swab before cannulating the vein. Only successful cannulations at the first attempt with a 20-G venous cannula (Venflon, Ohmeda, BOC Ohmeda, AB, Sweden) entered the study. A single and dedicated observer unaware of the gel applied recorded the pain scores as marked by subjects on a visual analogue scale (VAS) 110 cm (1 = no pain, 10 = worst possible pain). In addition, the observer rated local skin condition (blanching, erythema, induration, edema) at predetermined intervals. Cannulation was attempted one hour following application of the gel. The cannula was removed after one hour and local compression with pressure gauze lasted for 30 min.
VAS scores on cannulation, during cannula advancement and at regular intervals over the next 48 hr were compared using Wilcoxon rank sum test with continuity correction. Skin condition between the two drugs was compared using Pearsons Chi squared test with Yates continuity correction. A P < 0.05 was considered significant. A difference of 2 cm on the VAS to assess pain was considered significant. To detect this difference with a statistical power of 80% or more we calculated that we would need ten subjects.
| Results |
|---|
|
|
|---|
|
|
| Discussion |
|---|
|
|
|---|
Piroxicam gel was less effective in preventing pain on cannulation and on advancement of the venous cannula but was associated with a lesser incidence of skin induration and subsequent pain compared to EMLA. The vasoconstrictive effect of EMLA at the time of cannulation might be responsible for blanching.9,10 Blanching was present in all patients at the time of venous cannulation. Extravasation of blood in the surrounding tissue following decannulation may also contribute to inflammation. When the vasoconstrictive effects of EMLA wear off, there is a generalized local vasodilation, which may lead to erythema and swelling. In our study, EMLA treated hands were more painful over the 48 hr following venous cannulation.
Our study shows the advantageous analgesic effects of topical piroxicam in the period subsequent to the cannulation whereas the reduction of incidence of inflammatory skin signs was inconclusive. This warrants a larger study sample to substantiate clinical significance. Though inclusion of a placebo control would have better highlighted the analgesic efficacy of local piroxicam gel at the cannulation site, we felt it was not justified in volunteers. Although piroxicam did not fare well as compared to EMLA cream in decreasing pain during cannulation and cannula advancement, the advantageous analgesia profile of topically applied piroxicam in the period following cannulation may prove beneficial in adult outpatients as well as inpatients.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2 Payne-James JJ, Bray MJ, Kapadia S, Rana SK, Mcswiggan D, Silk DBA. Topical non-steroidal anti-inflammatory gel for the prevention of peripheral vein thrombophletitis. A double-blind, randomised, placebo-controlled trial in normal subjects. Anaesthesia 1992; 47: 3246.[Medline]
3 Irsfeld S, Klement W, Lipfert P. Dermal anaesthesia: comparison of EMLA cream with iontophoretic local anaesthesia. Br J Anaesth 1993; 71: 3758.
4 Smith AJ, Eggers KA, Stacey MRW. Topical ibuprofen for skin analgesia prior to venepuncture. Anaesthesia 1996; 51: 4957.[Medline]
5 Manner T, Kanto J, Iisalo E, Lindberg R, Viinamaki O, Scheinin M. Reduction of pain at venous cannulation in children with a eutectic mixture of lidocaine and prilocaine (EMLA® cream): comparison with placebo cream and no local premedication. Acta Anaesthesiol Scand 1987; 31: 7359.[Medline]
6 Insel PA. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Gilman AG, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW (Eds.). Goodman and Gilmans, The Pharmacological Basics of Therapeutics, 9th ed. New York: McGraw Hill; 1996: 61757.
7 OHanlon JJ, McCleane G, Muldoon T. Preoperative application of piroxicam gel compared to a local anaesthetic field block for postoperative analgesia. Acta Anaesthesiol Scand 1996; 40: 7158.[Medline]
8 van Vlymen JM, White PF. Outpatient anesthesia. In: Miller RD (Ed). Anesthesia, 5th ed. Philadelphia: Churchill Livingstone; 2000: 221340.
9 De Jong PC, Verburg MP, Lillieborg S. EMLA® cream versus ethyl-chloride spray: a comparison of the analgesic efficacy in children. Eur J Anaesthesiol 1990; 7: 47381.
10 Hallen B, Carlsson P, Uppfeldt A. Children study of a lignocaine-prilocaine cream to relieve the pain of venepuncture. Br J Anaesth 1985; 57: 3268.
This article has been cited by other articles:
![]() |
A. Agarwal, S. Gautam, D. Gupta, and U. Singh Transdermal diclofenac patch vs eutectic mixture of local anesthetics for venous cannulation pain: [Le diclofenac transdermique vs un melange eutectique d'anesthesiques locaux dans le traitement de la douleur associee au catheterisme veineux] Can J Anesth, March 1, 2007; 54(3): 196 - 200. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |